Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

Marco Ciaparrone, Orietta Caspiani, Giulio Bicciolo, Diego Signorelli, Ilaria Simonelli, Luca De Campora, Giorgio Mazzarella, Antonella Mecozzi, Curzio Pianelli, Angelo Camaioni, Piera Catalano, Patrizio Pasqualetti, Alfredo Fabiano, Marco Radici, Luca Marmiroli, Domenico Cristiano Corsi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.

Original languageEnglish
Pages (from-to)227-234
Number of pages8
JournalOncology
Volume89
DOIs
Publication statusPublished - Sep 18 2015

Fingerprint

DNA Repair
Cisplatin
Survival
Carcinoma, squamous cell of head and neck
Disease-Free Survival
Neoplasms
Multivariate Analysis
Immunohistochemistry
Recurrence

Keywords

  • Adjuvant concurrent chemoradiation
  • Cisplatin
  • ERCC1
  • Head and neck cancer
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Ciaparrone, M., Caspiani, O., Bicciolo, G., Signorelli, D., Simonelli, I., De Campora, L., ... Corsi, D. C. (2015). Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncology, 89, 227-234. https://doi.org/10.1159/000430447

Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. / Ciaparrone, Marco; Caspiani, Orietta; Bicciolo, Giulio; Signorelli, Diego; Simonelli, Ilaria; De Campora, Luca; Mazzarella, Giorgio; Mecozzi, Antonella; Pianelli, Curzio; Camaioni, Angelo; Catalano, Piera; Pasqualetti, Patrizio; Fabiano, Alfredo; Radici, Marco; Marmiroli, Luca; Corsi, Domenico Cristiano.

In: Oncology, Vol. 89, 18.09.2015, p. 227-234.

Research output: Contribution to journalArticle

Ciaparrone, M, Caspiani, O, Bicciolo, G, Signorelli, D, Simonelli, I, De Campora, L, Mazzarella, G, Mecozzi, A, Pianelli, C, Camaioni, A, Catalano, P, Pasqualetti, P, Fabiano, A, Radici, M, Marmiroli, L & Corsi, DC 2015, 'Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation', Oncology, vol. 89, pp. 227-234. https://doi.org/10.1159/000430447
Ciaparrone, Marco ; Caspiani, Orietta ; Bicciolo, Giulio ; Signorelli, Diego ; Simonelli, Ilaria ; De Campora, Luca ; Mazzarella, Giorgio ; Mecozzi, Antonella ; Pianelli, Curzio ; Camaioni, Angelo ; Catalano, Piera ; Pasqualetti, Patrizio ; Fabiano, Alfredo ; Radici, Marco ; Marmiroli, Luca ; Corsi, Domenico Cristiano. / Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. In: Oncology. 2015 ; Vol. 89. pp. 227-234.
@article{d495191bc4c545fca9a1198805d4ce9a,
title = "Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation",
abstract = "Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75{\%}) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95{\%} CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95{\%} CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95{\%} CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95{\%} CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95{\%} CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.",
keywords = "Adjuvant concurrent chemoradiation, Cisplatin, ERCC1, Head and neck cancer, Squamous cell carcinoma",
author = "Marco Ciaparrone and Orietta Caspiani and Giulio Bicciolo and Diego Signorelli and Ilaria Simonelli and {De Campora}, Luca and Giorgio Mazzarella and Antonella Mecozzi and Curzio Pianelli and Angelo Camaioni and Piera Catalano and Patrizio Pasqualetti and Alfredo Fabiano and Marco Radici and Luca Marmiroli and Corsi, {Domenico Cristiano}",
year = "2015",
month = "9",
day = "18",
doi = "10.1159/000430447",
language = "English",
volume = "89",
pages = "227--234",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",

}

TY - JOUR

T1 - Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

AU - Ciaparrone, Marco

AU - Caspiani, Orietta

AU - Bicciolo, Giulio

AU - Signorelli, Diego

AU - Simonelli, Ilaria

AU - De Campora, Luca

AU - Mazzarella, Giorgio

AU - Mecozzi, Antonella

AU - Pianelli, Curzio

AU - Camaioni, Angelo

AU - Catalano, Piera

AU - Pasqualetti, Patrizio

AU - Fabiano, Alfredo

AU - Radici, Marco

AU - Marmiroli, Luca

AU - Corsi, Domenico Cristiano

PY - 2015/9/18

Y1 - 2015/9/18

N2 - Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.

AB - Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation.

KW - Adjuvant concurrent chemoradiation

KW - Cisplatin

KW - ERCC1

KW - Head and neck cancer

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84942836469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942836469&partnerID=8YFLogxK

U2 - 10.1159/000430447

DO - 10.1159/000430447

M3 - Article

C2 - 26066774

AN - SCOPUS:84942836469

VL - 89

SP - 227

EP - 234

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -